Padcev

Chemical Nameenfortumab vedotin-ejfv
Dosage FormInjectable (intravenous; 20 mg/vial, 30 mg/vial)
Drug ClassMonoclonal antibodies
SystemUrinary
CompanyAstellas Pharma Inc.
Approval Year2019

Indication

  • Padcev is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, and a platinum-containing chemotherapy in the neoadjuvant/adjuvant, locally advanced or metastatic setting.
Last updated on 1/12/2021

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?